Jul 25 2023 |
et al., JAMA, doi:10.1001/jama.2023.11043 | Abatacept, Cenicriviroc, or Infliximab for Treatment of Adults Hospitalized With COVID-19 Pneumonia |
| 30% higher mortality (p=0.15), 8% worse improvement (p=0.62), and 1% improved recovery (p=0.91). RCT 723 hospitalized COVID-19 patients showing no significant difference in outcomes with cenicriviroc treatment. | ||
Mar 31 2023 |
et al., Journal of Global Antimicrobial Resistance, doi:10.1016/j.jgar.2022.12.004 | Cenicriviroc for the treatment of COVID-19: first interim results of a randomised, placebo-controlled, investigator-initiated, double-blind phase II trial |
| 500% higher need for oxygen therapy (p=0.26), 100% worse recovery (p=0.55), and 17% longer hospitalization (p=0.42). RCT 30 hospitalized COVID-19 patients showing no significant difference in clinical improvement with cenicriviroc (CVC) treatment compared to placebo. | ||
Mar 3 2023 |
et al., eClinicalMedicine, doi:10.1016/j.eclinm.2023.101889 | Report of the first seven agents in the I-SPY COVID trial: a phase 2, open label, adaptive platform randomised controlled trial |
| 24% higher mortality (p=0.28) and 14% worse recovery (p=0.46). RCT 261 severe COVID-19 patients showing no significant difference in outcomes with cenicriviroc. | ||
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.